Protalix BioTherapeutics (NASDAQ:PLX) biopharma firm is expected to report fourth quarter earnings results, before the bell, on Tuesday 6th March 2018.
Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.06 per share from revenue of $ 9.70 million.
Looking ahead, the full year loss are expected at $ 0.29 per share on the revenues of $ 27.76 million.
During the same quarter last year, the company reportedly had loss of $ 0.13 per share on $ 2.08 million in revenue.
The Company recorded total revenues of $16.8 million for the nine-month period, Where as net loss for the same period were $32.1 million, or $0.25 per share.
ProCellEx, will provide a corporate update on Tuesday, March 6, 2018 at 8:30 am ET. To participate in the conference call, please dial +1-844-358-6760 (United States) or +1-478-219-0004 (International) with Conference ID number 2636229.